List of works - Annette von Delft

'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy

scientific article published on 13 March 2013

A white-knuckle ride of open COVID drug discovery

scientific article published on 14 June 2021

Accelerating antiviral drug discovery: lessons from COVID-19

scientific article published on 12 May 2023

An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic

scientific article published on 26 December 2023

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans

scientific article published on 16 October 2015

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.

scientific article published on 29 August 2013

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.

scientific article published on 10 April 2017

HCV genotype-3a T cell immunity: specificity, function and impact of therapy

scientific article (publication date: November 2012)

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection

scientific article published on 2 August 2016

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia

scientific article published on 20 December 2021

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans

scientific article published on 01 June 2020

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors

scientific article published on 10 November 2023

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

scientific article published in June 2022

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Quantitative trait loci mapping of the mouse plasma proteome (pQTL)

scientific article

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design

scientific article

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes

scientific article

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes

scientific article published on 09 June 2020

List of works by Annette von Delft

'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy

A white-knuckle ride of open COVID drug discovery

Accelerating antiviral drug discovery: lessons from COVID-19

An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.

HCV genotype-3a T cell immunity: specificity, function and impact of therapy

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Quantitative trait loci mapping of the mouse plasma proteome (pQTL)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes